Last reviewed · How we verify
abatacept, rituximab or tocilizumab
Abatacept, rituximab, and tocilizumab are marketed drugs developed by University Hospital, Strasbourg, France, with a key composition patent expiring in 2028. These drugs leverage distinct mechanisms to address primary indications, positioning them as established treatments in their respective therapeutic areas. The primary risk is the patent expiry in 2028, which could lead to increased competition from generics and biosimilars.
At a glance
| Generic name | abatacept, rituximab or tocilizumab |
|---|---|
| Sponsor | University Hospital, Strasbourg, France |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis (PHASE4)
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty (PHASE2)
- RA-PRO PRAGMATIC TRIAL (PHASE3)
- Clinical Trial Evaluating Methotrexate or Leflunomide + Targeted Therapy Versus Methotrexate or Leflunomide + Sulfasalazine + Hydroxychloroquine in Patients With Rheumatoid Arthritis and Insufficient Response to Methotrexate or Leflunomide (PHASE4)
- Korean College of Rheumatology Biologics and Targeted Therapy Registry
- Using Adalimumab Serum Concentration to Choose a Subsequent Biological DMARD in Rheumatoid Arthritis Patients Failing Adalimumab Treatment (PHASE4)
- Cardiovascular Risk and Chronic Inflammatory Rheumatism (NA)
- Predicting Hospitalized Infection in Patients With Chronic Inflammatory Arthritis Treated With Biological Drugs
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: